Liminal BioSciences Inc.

Good day and welcome to the Liminal Biosciences, Inc. First Quarter 2022 Results Conference Call. Today's conference is being recorded. There will be a question and answer session after today's prepared remarks, where we will only be taking questions from financial analysts. At this time, I would like to turn the conference over to Chanel and Amdar. Please go ahead.

Thank you, Operator. Good morning ladies and gentlemen, my name is Srinale Enamda and I'm the Investor Relations and Communications Manager at Liminal Biosciences. This recorded webcast will be accessible from the Investor Resources page on the Liminal Biosciences website and you'll be able to replay later on today. For those of you dialling in, you can find a copy of our presentation slides on the webcast section of the website or via the conference call portal. Moving on to slide 2, I'd like to remind everyone that we will be making forward-looking statements today during the webcast, including remarks or current expectations concerning future developments of the pipeline, the properties of our product candidates, the timing or initiation of preclinical and clinical trials, including the nature of preclinical and clinical trials, and potential therapeutic areas, regulatory plans, financing plans, our ability to resolve the NASDAQ listing deficiency and regain compliance with the NASDAQ listing rules, Our company, its financial position, the impact of COVID-19 on our business and possible changes in the industry and competitive environment. These forward-looking statements are based on our current expectations and beliefs and on information currently available to us. These statements are subject to risks and uncertainties, including those contained in our updated reports that we file with the U.S. Securities and Exchange Commission, or SEC, and Canadian Securities Commissions from time to time. including our annual report on Form 20F and our 6K containing our press release of the results for the first quarter ended March 31st, 2022, each of which we have filed with the SEC and ONCEDA that could cause actual results to differ materially from those containing the forward-looking statements. Please note that these forward-looking statements made during the webcast speak only of our expectations as of today's date and Liminal Biosciences undertakes no obligation to update these statements to reflect subsequent events or circumstances. except to the extent required by law. As stated on slide 3, during this morning's webcast, Liminal's Chief Executive Officer, Mr Bruce Pritchard, will provide a business update. Then, Ms Nicole Russo, our Interim Chief Financial Officer, will present the financial and operational highlights for the first quarter ended March 31, 2022. We will then follow with closing comments on the expected near-term milestones and a short question and answer period for financial analysts only. Mr. Patrick Sartori, Liminal Biosciences President, will also be joining us for the Q&A session. I'd now like to welcome Liminal's Chief Executive Officer, Mr. Bruce Pritchard, to the call, who will give a brief update on our research and development programs, as well as Liminal's anticipated key upcoming data catalysts. Bruce, over to you.

That's great. Thank you very much, Renal, and good morning, everyone. If I could now ask you all to move to slide four in the presentation And I'll provide a brief update on our pipeline and expected near-term milestones. As we previously disclosed, our lead asset, FasagiPras, completed a phase one multiple ascending dose or MAD clinical trial earlier this year, which provided data to demonstrate that the major metabolite of FasagiPras was the glutamine conjugate. This provides an opportunity for FasagiPras' potential development in diseases associated with high plasma ammonia concentrations. In the second quarter of 2022, subject to the usual regulatory approvals, we expect to initiate a phase one single ascending dose clinical trial designed as a head-to-head comparison with sodium phenylbutyrate to provide us with further data to determine if physagioprase is worth developing for one of the many potential indications where nitrogen scavenging is beneficial. We look forward to providing more information on this upcoming clinical trial in the near future, and expect to provide an update on the outcome of this additional research in the second half of 2022. We've also made significant progress on the identification of high-potency small molecule antagonists of GPR84, including potential selected candidates for development from different structural classes to those GPR84 antagonists for which data has already been published. Work on selecting a lead product candidate to advance into the clinic is ongoing from the company's current lead compounds, and is progressing well with plans to finalize candidate selection later on in 2022. Similar to the GPR84 antagonist program, we're also making good progress on developing potential OXR1 antagonist candidates. And although there are a number of biologics, primarily antibodies approved for the treatment of certain eosinophilic driven diseases, a small molecule approach to this pathway may provide a differentiated small molecule therapy. So moving forward, we have multiple opportunities for growth in the year ahead. And in summary, we're focused on value creation for patients, our shareholders, and our employees. At this point in the presentation, I'll hand over to Nicole Rousseau, who will talk us through our financial and operating results for the quarter ended March 31st, 2022. So Nicole, over to you.